Yoga for the primary prevention of cardiovascular disease

被引:48
作者
Hartley, Louise [1 ]
Dyakova, Mariana [1 ]
Holmes, Jennifer [2 ]
Clarke, Aileen [1 ]
Lee, Myeong Soo [3 ]
Ernst, Edzard [4 ]
Rees, Karen [1 ]
机构
[1] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry CV4 7AL, Warwick, England
[2] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, Warwick, England
[3] Korea Inst Oriental Med, Med Res Div, Taejon, South Korea
[4] Univ Exeter, Peninsula Med Sch, Complementary Med Dept, Exeter, Devon, England
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2014年 / 05期
关键词
METABOLIC SYNDROME; HATHA-YOGA; EXERCISE; ADULTS; INTERVENTION; METAANALYSIS; PUBLICATION; PREVALENCE; BIAS;
D O I
10.1002/14651858.CD010072.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A sedentary lifestyle and stress are major risk factors for cardiovascular disease (CVD). Since yoga involves exercise and is thought to help in stress reduction it may be an effective strategy in the primary prevention of CVD. Objectives To determine the effect of any type of yoga on the primary prevention of CVD. Search methods We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11) in The Cochrane Library; MEDLINE (Ovid) (1946 to November Week 3 2013); EMBASE Classic + EMBASE (Ovid) (1947 to 2013 Week 48); Web of Science (Thomson Reuters) (1970 to 4 December 2013); Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database and Health Economics Evaluations Database (Issue 4 of 4, 2013) in The Cochrane Library. We also searched a number of Asian databases and the Allied and Complementary Medicine Database (AMED) (inception to December 2012). We searched trial registers and reference lists of reviews and articles, and approached experts in the field. We applied no language restrictions. Selection criteria Randomised controlled trials lasting at least three months involving healthy adults or those at high risk of CVD. Trials examined any type of yoga and the comparison group was no intervention or minimal intervention. Outcomes of interest were clinical CVD events and major CVD risk factors. We did not include any trials that involved multifactorial lifestyle interventions or weight loss. Data collection and analysis Two authors independently selected trials for inclusion, extracted data and assessed the risk of bias. Main results We identified 11 trials (800 participants) and two ongoing studies. Style and duration of yoga differed between trials. Half of the participants recruited to the studies were at high risk of CVD. Most of studies were at risk of performance bias, with inadequate details reported in many of them to judge the risk of selection bias. No study reported cardiovascular mortality, all-cause mortality or non-fatal events, and most studies were small and short-term. There was substantial heterogeneity between studies making it impossible to combine studies statistically for systolic blood pressure and total cholesterol. Yoga was found to produce reductions in diastolic blood pressure (mean difference (MD) -2.90 mmHg, 95% confidence interval (CI) -4.52 to -1.28), which was stable on sensitivity analysis, triglycerides (MD -0.27 mmol/l, 95% CI -0.44 to -0.11) and high-density lipoprotein (HDL) cholesterol (MD 0.08 mmol/l, 95% CI 0.02 to 0.14). However, the contributing studies were small, short-term and at unclear or high risk of bias. There was no clear evidence of a difference between groups for low-density lipoprotein (LDL) cholesterol (MD -0.09 mmol/l, 95% CI -0.48 to 0.30), although there was moderate statistical heterogeneity. Adverse events, occurrence of type 2 diabetes and costs were not reported in any of the included studies. Quality of life was measured in three trials but the results were inconclusive. Authors' conclusions The limited evidence comes from small, short-term, low-quality studies. There is some evidence that yoga has favourable effects on diastolic blood pressure, HDL cholesterol and triglycerides, and uncertain effects on LDL cholesterol. These results should be considered as exploratory and interpreted with caution.
引用
收藏
页数:51
相关论文
共 50 条
[21]   Rethinking Aspirin for the Primary Prevention of Cardiovascular Disease [J].
Lin, Kenneth W. ;
Middleton, Jennifer .
AMERICAN FAMILY PHYSICIAN, 2019, 99 (11) :670-671
[22]   Primary Prevention of Cardiovascular Disease in Older Adults [J].
Barry, Arden R. ;
O'Neill, Deirdre E. ;
Graham, Michelle M. .
CANADIAN JOURNAL OF CARDIOLOGY, 2016, 32 (09) :1074-1081
[23]   RETRACTED: Transcendental meditation for the primary prevention of cardiovascular disease (Retracted Article) [J].
Hartley, Louise ;
Mavrodaris, Angelique ;
Flowers, Nadine ;
Ernst, Edzard ;
Rees, Karen .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (12)
[24]   Evidence-based Use of Statins for Primary Prevention of Cardiovascular Disease [J].
Minder, C. Michael ;
Blaha, Michael J. ;
Horne, Aaron ;
Michos, Erin D. ;
Kaul, Sanjay ;
Blumenthal, Roger S. .
AMERICAN JOURNAL OF MEDICINE, 2012, 125 (05) :440-446
[25]   Cardiovascular disease: primary prevention, disease modulation and regenerative therapy [J].
Sultan, Sherif ;
Hynes, Niamh .
VASCULAR, 2012, 20 (05) :243-250
[26]   The impact of the Polish national Programme of Cardiovascular Disease Prevention on the quality of primary cardiovascular disease prevention in clinical practice [J].
Pajak, Andrzej ;
Szafraniec, Krystyna ;
Janion, Marianna ;
Szpak, Andrzej ;
Wizner, Barbara ;
Wolfshaut-Wolak, Renata ;
Broda, Grazyna ;
Cichocka, Izabela ;
Drygas, Wojciech ;
Gasior, Zbigniew ;
Grodzicki, Tomasz ;
Zdrojewski, Tomasz .
KARDIOLOGIA POLSKA, 2010, 68 (12) :1332-1343
[27]   Primary prevention of cardiovascular disease in older adults in China [J].
Jian Yong ;
Dong Lin ;
Xue-Rui Tan .
World Journal of Clinical Cases, 2017, (09) :349-359
[28]   Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity [J].
Miedema, Michael D. ;
Huguelet, Joseph ;
Virani, Salim S. .
CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (01) :1-6
[29]   Improving Behavioral Counseling for Primary Cardiovascular Disease Prevention [J].
Lavie, Carl J. ;
Franklin, Barry A. ;
Ferdinand, Keith C. .
JAMA CARDIOLOGY, 2022, 7 (09) :886-888
[30]   Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease [J].
Raju, Nina ;
Sobieraj-Teague, Magdalena ;
Hirsh, Jack ;
O'Donnell, Martin ;
Eikelboom, John .
AMERICAN JOURNAL OF MEDICINE, 2011, 124 (07) :621-629